Drug intelligence / Profile preview

CH-26

Development stage: Unknown
Lead developer: Curanter
Administration: Oral

Overview

**CH-26** is a commercially listed oral homeopathic remedy from Curanter Homeo, presented on the company's product listing as \"CH - 26 (Osteoporosis Drop).\" The available public product listing does not disclose its active ingredients, homeopathic dilutions, pharmacological target, mechanism of action, clinical evidence, regulatory approval status, or formal development program. It is therefore best characterized as a retail homeopathic product marketed for osteoporosis-related use rather than a clinically characterized drug candidate. ([curanter.com](https://curanter.com/))

Other names: Osteoporosis Drop

Beyond the preview

Go deeper on CH-26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH-26.

Explore the full profile